The differential response of CD276-positive ESCC PSO and CD276-negative NC PSO following iPSC CD276-targeted CAR-NK treatment indicates the on-target effect and the potential off-tumor toxicity of iPSC CD276-targeted CAR-NK in future clinical trials. Here, CD276 is linked to esophageal squamous cell carcinoma.